<- Go Home
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Market Cap
$233.4M
Volume
495.1K
Cash and Equivalents
$10.5M
EBITDA
-$45.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$33.4M
Profit Margin
N/A
52 Week High
$6.60
52 Week Low
$1.00
Dividend
N/A
Price / Book Value
1.44
Price / Earnings
-5.77
Price / Tangible Book Value
1.44
Enterprise Value
$142.7M
Enterprise Value / EBITDA
-3.56
Operating Income
-$49.0M
Return on Equity
14.96%
Return on Assets
-28.20
Cash and Short Term Investments
$96.6M
Debt
$6.0M
Equity
$151.5M
Revenue
N/A
Unlevered FCF
-$22.1M
Sector
Biotechnology
Category
N/A